Treatment for advanced prostate cancer has evolved significantly in recent years. Today, combination therapies are recommended to slow disease progression and improve survival.
Hormone therapy is the backbone of treatment for advanced prostate cancer. It works by lowering testosterone, the hormone that fuels prostate cancer growth.
Recent studies show that combining ADT with an androgen receptor inhibitor (ARI) improves outcomes and delays disease progression. This combination therapy is recommended early for patients with hormone-sensitive prostate cancer, even before the cancer becomes resistant to hormone therapy.
UPNT’s radiation oncologists use advanced techniques such as Stereotactic Body Radiation Therapy (SBRT), which delivers highly precise doses of radiation with minimal damage to surrounding tissues.
UPNT is proud to offer access to clinical trials, giving patients the opportunity to receive promising new treatments before they become widely available. Clinical trials may include immunotherapy, PARP inhibitors, or targeted therapies for patients with specific genetic mutations (e.g., BRCA mutations).
At UPNT, we combine expertise in radiation oncology with a collaborative approach, working closely with leading medical oncologists to deliver the best care possible. Our commitment to personalized treatment plans, access to clinical trials, and innovative therapies ensures that patients receive the most up-to-date and effective care available.